Camp4 CFO buys 10,000 shares at $3.96
Camp4 Therapeutics’ CFO reported an open-market share purchase held in a spouse’s brokerage account, alongside updated direct holdings.
Rhea-AI Filing Summary
Camp4 Therapeutics Corp (CAMP) reported that Chief Financial Officer Kelly Gold filed a Form 4 showing an open-market purchase associated with her household of 10,000 shares of Common Stock on August 31, 2026, at a weighted average price of $3.96 per share, in multiple trades between $3.88 and $4.00. These shares are held in a brokerage account in the name of her spouse, over which she does not exercise investment control and for which she disclaims beneficial ownership except for any pecuniary interest. Separately, Gold is reported to hold 76,467 shares directly, including 2,039 shares previously acquired under Camp4 Therapeutics Corporation’s Employee Stock Purchase Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,000 shares
Net Buy
2 txns
Insider
Gold Kelly
Role
Chief Financial Officer
Bought
10,000 shs ($40K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F2 | 10,000 | $3.96 | $40K |
| holding | Common Stock F3 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 10,000 shares (Indirect, By Spouse);
Common Stock — 76,467 shares (Direct)
Footnotes (3)
- F1. The shares reported herein were purchased in the open market in multiple transactions at prices ranging from $3.88 to $4.00, inclusive. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to CAMP4 Therapeutics Corporation, any security holder of CAMP4, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2. The shares reported herein are held in a brokerage account in the name of David Gold, the Reporting Person's spouse. The Reporting Person does not exercise investment control over this account. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
- F3. Includes 2,039 shares previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") in a transaction that was exempt under Rule 16b-3(c).
Key Figures
Shares purchased: 10,000 shares of Common Stock
Weighted average purchase price: $3.96 per share
Purchase price range: $3.88–$4.00 per share
+3 more
6 metrics
Shares purchased
10,000 shares of Common Stock
Open-market purchase associated with CFO’s household on August 31, 2026
Weighted average purchase price
$3.96 per share
10,000-share open-market purchase in trades from $3.88 to $4.00
Purchase price range
$3.88–$4.00 per share
Range of prices for the multiple transactions comprising the 10,000-share purchase
Indirect holdings via spouse account
10,000 shares
Shares held in a brokerage account in the name of David Gold
Direct holdings after transaction
76,467 shares
Common Stock held directly by CFO after the reported transactions
ESPP shares included in direct holdings
2,039 shares
Previously acquired under the Camp4 Therapeutics Corporation Employee Stock Purchase Plan
Key Terms
weighted average price, beneficial ownership, pecuniary interest, Employee Stock Purchase Plan, +1 more
5 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of her pecuniary interest"
Employee Stock Purchase Plan financial
"previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3(c) regulatory
"in a transaction that was exempt under Rule 16b-3(c)"
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
FAQ
What insider transaction did CAMP’s CFO report on this Form 4?
The filing reports an open-market purchase of 10,000 shares of Common Stock on August 31, 2026, at a weighted average price of $3.96 per share, executed in multiple trades between $3.88 and $4.00.
What are the CFO’s reported direct holdings of CAMP common stock after this filing?
The filing lists 76,467 shares of Camp4 Therapeutics Common Stock as held directly by the CFO, which includes 2,039 shares previously acquired under the company’s Employee Stock Purchase Plan.
Were the CAMP insider transactions made under a Rule 10b5-1 trading plan?
No. The filing indicates that no Rule 10b5-1 trading plan is affirmed for these transactions; they are not reported as being executed pursuant to such a pre-arranged plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
